# The Coming Divide in Cannabis: Why the U.S. Market Remains Out of Reach for Global Operators > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-research-barriers-us-cannabis-market/ > **Published:** 2026-03-05T15:36:18-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:11:28-04:00 > **Clinical Summary:** Explore cannabinoid research barriers in the U.S. cannabis market and how federal regulations impact clinical evidence and drug development. --- ✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyResearchCBDTHCIndustry Why This Matters Patients seeking cannabinoid-based treatments may find that the medicines with the strongest clinical evidence available elsewhere in the world remain inaccessible in the U.S. not because of safety concerns, but because of who is permitted to conduct the research in the first place. Clinical Summary The United States maintains a uniquely fragmented regulatory environment for [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/), where federal scheduling under the Controlled Substances Act creates structural barriers that foreign operators and even domestic companies struggle to navigate when developing cannabinoid-based medicines. Unlike pharmaceuticals that can be studied and approved through relatively standardized international pathways, [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) in the U.S. requires federal authorization at multiple levels, creating a system where control over the science is inseparable from control over the market. This regulatory architecture effectively determines not just who can sell cannabis medicines in the U.S., but who can generate the clinical evidence needed to legitimize them globally. Dr. Caplan’s Take “When federal law decides who gets to ask the scientific questions, it has already decided who gets to profit from the answers, and that is a research integrity problem before it is a market problem.” Clinical Perspective The regulatory fragmentation between state-legal cannabis programs and federal scheduling creates a significant barrier to rigorous [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) that ultimately impacts patient access to standardized, evidence-based cannabinoid therapeutics. While state markets have expanded rapidly, the absence of federal oversight means most products lack the quality controls and clinical validation that physicians typically expect from pharmaceutical interventions. This divide incentivizes companies to pursue easier pathways through unregulated state channels rather than undertaking the costly research necessary to establish safety and efficacy profiles. Until cannabinoid-based medicines can be studied under unified federal frameworks, clinicians will continue operating with limited comparative data and patients may miss opportunities for truly therapeutic dosing and formulation strategies. The market’s current structure prioritizes commercial scale over clinical rigor, which is the inverse of what evidence-based medicine requires. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+The+Coming+Divide+in+%3Cb%3ECannabis%3C%2Fb%3E%3A+Why+the+U.S.+Market+Remains+Out+of+Reach+for+Global+Operators+%40drcaplan&url=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoming-divide-cannabis-why-u-172000342.html) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoming-divide-cannabis-why-u-172000342.html) [🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+The+Coming+Divide+in+%3Cb%3ECannabis%3C%2Fb%3E%3A+Why+the+U.S.+Market+Remains+Out+of+Reach+for+Global+Operators+%E2%80%94+via+%40drcaplan.bsky.social+https%3A%2F%2Ffinance.yahoo.com%2Fnews%2Fcoming-divide-cannabis-why-u-172000342.html) [📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/) [📝 Read more on Substack](https://substack.com/@doctorapproved) [🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://finance.yahoo.com/news/coming-divide-cannabis-why-u-172000342.html](https://finance.yahoo.com/news/coming-divide-cannabis-why-u-172000342.html) Further Reading Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 10, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/) Research Digest[Daily Digest 2026-03-07](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [US Cannabis Rescheduling: A Victory or a Federal Trap?](https://cedclinic.com/cannabis-federal-policy-impacts-patient-access/) An in-depth analysis of the implications of cannabis rescheduling on research and market access in the United States. [Read More](https://cedclinic.com/cannabis-federal-policy-impacts-patient-access/) Medical Marijuana Reclassification: New Research Opportunities Explore how reclassification efforts could open new avenues for cannabis research and [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/). Discover Insights [Cannabis Pharmaceuticals Business Research Report 2026](https://cedclinic.com/cannabis-pharmaceuticals-business-research-report-2026-an-111-1-billion-market-by/) A comprehensive market report highlighting growth trends and research developments in cannabis pharmaceuticals. [View Report](https://cedclinic.com/cannabis-pharmaceuticals-business-research-report-2026-an-111-1-billion-market-by/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).